lunes, 1 de abril de 2013

National Guideline Clearinghouse | Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.

full-text:
National Guideline Clearinghouse | Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.

National Guideline Clearinghouse (NGC)


March 25, 2013








Guideline Title



Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.


 





Bibliographic Source(s)




National Institute for Health and Clinical Excellence (NICE). Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma. London (UK): National Institute for Health and Clinical Excellence (NICE); 2012 Dec. 45 p. (Technology appraisal guidance; no. 269).





 


Guideline Status



This is the current release of the guideline.





No hay comentarios:

Publicar un comentario